Adam Waxman, MD
Internal Medicine · Philadelphia, PANPI 1669766275
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $150 of the $218 with a category attached, or 68.7%. Janssen Scientific Affairs, LLC accounts for 68.7% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $109.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$150
- AstraZeneca$68
Across 54 payments — averaging $16,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$631K
- Janssen Research & Development, LLC$263K
What the payments were for
- Consulting fees$15069%
- Education$6831%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $150 |
| AstraZeneca | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALVEY$150
How this compares
$218 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 75 | $1,295,642 |
| Lenalidomide | 76 | $989,939 |
| PomalystPomalidomide | 23 | $485,646 |
| BrukinsaZanubrutinib | 17 | $169,268 |
| XareltoRivaroxaban | 11 | $6,112 |
| ValacyclovirValacyclovir Hcl | 52 | $1,001 |
| Acyclovir | 44 | $999 |
| Mirtazapine | 19 | $315 |
| Dexamethasone | 20 | $312 |
| Montelukast Sodium | 17 | $275 |
| Fluticasone Propionate | 13 | $149 |
| Oxycodone Hcl | 20 | $133 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.